Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norelgestromin + ethinyl estradiol
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
The transdermal contraceptive system, specifically the norelgestromin and ethinyl estradiol transdermal system (marketed as Ortho Evra), is a combined hormonal contraceptive delivered via a skin patch. Developed by Johnson & Johnson's Ortho-McNeil Pharmaceutical, it was the first contraceptive patch approved by the FDA in 2001. The system releases a daily dose of 150 micrograms of norelgestromin (a progestin) and 35 micrograms of ethinyl estradiol (an estrogen) into the systemic circulation over a seven-day period. Its primary mechanism of action is the suppression of gonadotropins, which inhibits ovulation. Secondary contraceptive effects include increasing the viscosity of cervical mucus to prevent sperm penetration and altering the endometrium to reduce the likelihood of implantation. It is indicated for the prevention of pregnancy in women who choose a transdermal method of birth control.
- Brand names
- Ortho EvraXulaneZafemyEvra
- Other names
- norelgestromin/ethinyl estradiol transdermal systemtransdermal contraceptive patch
02
Targets
ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)
Beyond the preview
Go deeper on norelgestromin + ethinyl estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norelgestromin + ethinyl estradiol.